CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 16 enrolled
Drug / intervention
Ketaminedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03553758
NCT03553758Phase 3Completed

Electroencephalogram Studies of Induction and Recovery From Ketamine-Induced General Anesthesia

Massachusetts General Hospital·interventional·Posted Jun 12, 2018·Updated Aug 26, 2020

In Brief

A Phase 3 clinical trial evaluating Ketamine for Anesthesia. Completed, enrolled 16 participants across 1 site.

Detailed Summary

We are doing this research study to find out how and where ketamine acts in the brain. Ketamine is an anesthetic (a drug or agent used to decrease or eliminate the feeling of pain by putting you in an unconscious state). We will look at the brain using a machine that records the brain's electrical activity, called an electroencephalogram (EEG). We will assess how it impacts patient's pain responses.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAnesthesia
CountriesUnited States
Collaborators--

Timeline

Phase 3CompletedFinished
20192020202120222023202420252026
First PostedJun 12, 2018
Enrollment StartNov 1, 2018
Primary CompletionFeb 1, 2019
Study CompletionAug 1, 2019
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 8.1 years ago

Interventions

Ketaminedrug

Subjects' brain waves will be monitored by EEG recording under ketamine general anesthesia over the course of approximately 60 minutes. Patients pain and dissociation will be assessed before the induction of ketamine and periodically after. Approximately 1 hour after ketamine induction, Midazolam will be administered to reduce patient dissociation.